Dr Reddy’s arm, Curis ink pact to develop select cancer therapies

23 Jan 2015 Evaluate

US-based biotechnology company Curis, Inc has entered into an exclusive collaboration pact with Aurigene Discovery Technologies, an independent wholly-owned subsidiary of Dr Reddy’s Laboratories for focusing on development of select cancer therapies.

The collaboration provides for inclusion of multiple programmes and Curis retains the option to license compounds once a development candidate is nominated within each respective programme. The collaboration focuses on immuno-oncology and selected precision oncology targets.

The partnership draws from each company’s respective areas of expertise, with Aurigene having the responsibility for conducting all discovery and pre-clinical activities while Curis is responsible for all clinical development, regulatory and commercialisation efforts worldwide, excluding India and Russia.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×